Renowned strategist Tom Lee says to buy these 29 stocks that were ravaged by the pandemic but now poised to boom as the world reopens – and they're all top-rated by 3 different investing strategies

Financial world news, market analysis, investment scam prevention tips and more ✔️ Learn all there is to know about the asset management industry. This magazine is crafted specifically for those who are interested in diving into the global asset management world. Getty Images / HandoutFundstrat's Tom Lee has said companies that were at the center of the pandemic sell-off — and will be at the center of the economic recovery — are investors' best opportunity in 2021. Lee says a select group of those "epicenter" stocks get simultaneous "Overweight" or top ratings from three of his firm's strategy leaders. His latest forecast calls for the S&P 500 to trade at 4,300 by the end of the year, with value stocks outperforming growth stocks. Visit Business Insider's homepage for more stories. The stock market's historic rally from its lows in March has been historic in its speed and scope, but Fundstrat head of research Tom Lee says it's also been historically normal. In a note to clients, Lee says that when stocks go through a major sell-off, they typically come back at about the same speed they fell. It almost resembles Newton's Third Law of Motion - "for every action, there is an equal and opposite reaction." He illustrates the point with this series of graphs that covers all of the market's slumps of 36% or more since 1932.   Fundstrat head of research Tom Lee says that the major stock market To keep reading about Renowned strategist Tom Lee says to buy these 29 stocks that were ravaged by the pandemic but now poised to boom as the world reopens – and they're all top-rated by 3 different investing strategies, Click on the link. Seoul, Korea
http://dlvr.it/RpQkjb

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint